OVERLAND PARK, Kan., July 28, 2020 /PRNewswire/ — Nemechek Technologies has applied to the World Health Organization (WHO) for Emergency Use Listing (EUL) of its Vitality Smartcable device. In January, the WHO Director-General declared that the coronavirus outbreak constituted an international public health emergency. The EUL procedure was developed to help member states choose diagnostics, vaccines, and therapeutics based on available quality, safety, and performance data. The Vitality Smartcable is a transcutaneous auricular vagus nerve stimulator (taVNS) operated by a smartphone and is capable of significantly lowering inflammation through electronical impulses delivered through a clip that fits comfortably on the ear. Dr. Nemechek says, “Stimulation
Nemechek Technologies is a fast growing company with unique expertise in neuromodulation that is positioned to provide a variety of solutions for individuals with both acute and chronic symptoms from COVID-19 infection and other conditions.
We are currently looking for interested partners to fulfill our mission and make a difference in the lives of COVID-19 infected individuals.
innovative bioelectric technology
As the Coronavirus pandemic continues to spread worldwide, it is becoming readily apparent that modern medicine is not prepared to fight the unique disease processes triggered by COVID-19 infection. Nemechek Technologies is a small company with cutting edge expertise and a clear vision of the medical needs of patients afflicted with COVID-19.
Our company’s vision for COVID-19 therapies arose from Dr. Nemechek’s 20 years experience as an HIV expert, combined with his recent discoveries involving the reversal of nervous system damage though the proper regulation of inflammation within the body. Dr. Nemechek believes that the future of health maintenance will be based on minimizing the stress of systemic inflammation.
Our Mission is to demonstrate that vagus nerve stimulation is an effective therapy for both acute and convalescent COVID-19 patients and to produce high quality transcutaneous vagus nerve stimulators for their use. Beyond COVID-19, vagus nerve stimulation and related products such as HRV monitors have potential for other autonomic health and wellness applications.
How the Vitality Neuromodulator Can Aid in the Fight Against COVID-19
Patients hospitalized with COVID-19 are predominantly dying of respiratory failure due to a surge of pro-inflammatory protein molecules called cytokines that regulate inflammation. In some COVID-19 patients, an excessive inflammatory reaction known as a “cytokine storm” will trigger acute respiratory distress syndrome. This severe form of lung injury is why many patients require mechanical ventilation.
A potential solution to this deadly, unregulated immune response may be a mild electrical current applied to the vagus nerve. Dr. Nemechek’s method, known as transcutaneous auricular vagus nerve stimulation (taVNS), delivers a barely perceptible micro-current through a specially designed clip that fits comfortably on the ear.
Nemechek Technologies has applied for an Emergency Use Application (EUA) from the FDA as well as an Emergency Use Listing (EUL) from the World Health Organization to use vagus nerve stimulation as adjunctive therapy in persons struggling from the acute or chronic symptoms of COVID-19 infection.
OVERLAND PARK, KS, July 20, 2020 — Nemechek Technologies has applied to the FDA for an Emergency Use Authorization (EUA) for its Vitality Smartcable device. Originally sold as a wellness device, the Vitality Smartcable is currently being used in a COVID-19 clinical trial to assess the therapeutic effect of transcutaneous auricular vagus nerve stimulation (taVNS). The study will measure the clinical impact on ICU admissions, intubations, and mortality in patients with pneumonia from coronavirus infection. We are confident the trial will show that taVNS can improve outcomes by its effect in suppressing the uncontrolled surge of inflammation-signaling molecules known as a
Vagus Nerve Stimulation (VNS) Clinical Trial Begins Enrolling COVID-19 Patients OVERLAND PARK, Kan., July 9, 2020 /PRNewswire/ — COVID-19 patients have begun enrolling in an interventional clinical trial at Hospital Virgen del Carmen in Zarate, Argentina. The study will evaluate the therapeutic effect of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with pneumonia associated with the disease. Hospital Virgen del Carmen, the first health center in South America to conduct such a study, will use Vitality Smartcable taVNS devices supplied by Nemechek Technologies, LLC. Some COVID-19 patients have an excessive inflammatory immune response known as a “cytokine storm.” Vagus nerve stimulation is shown to suppress inflammatory reactions
Is Bio-Electric Medicine the Next Frontier of Therapy for Coronavirus Victims? Just Published – Dr. Patrick Nemechek proposes new technology to suppress COVID-19 cytokine storm. Overland Park, Kansas, June 29, 2020 – Nemechek Technologies, LLC announced the publication of a peer-reviewed article by Patrick Nemechek D.O. in The Journal of Integrative Clinical Medicine. Entitled, ‘Transcutaneous Auricular Vagus Nerve Stimulation Holds the Potential to Suppress the COVID-19 Cytokine Storm’, the article explains the science behind the inflammatory reflex and how vagus nerve stimulation may be a cost-effective and life-saving therapy. Patients hospitalized with COVID-19 are predominantly dying of respiratory failure
‘Vagus Nerve Stimulation is an Ideal Therapeutic Candidate for COVID-19 Infection’ Patrick Nemechek, D.O. – Published in The Journal of Emerging Diseases and Virology OVERLAND PARK, KANSAS, UNITED STATES, June 22, 2020 /EINPresswire.com/ — Nemechek Technologies, LLC announced the publication of a peer-reviewed article by Patrick Nemechek D.O. on the advantages of vagus nerve stimulation (VNS) as a candidate therapy for COVID-19. VNS is largely unrecognized as a therapeutic tool to regulate the cytokine storm in hospitalized patients. Patients hospitalized with COVID-19 are predominantly dying of respiratory failure due to a surge of pro-inflammatory cytokines triggering acute respiratory distress syndrome